Why MRD is a hot topic in CLL and how it should be used

Paolo Ghia, MD, PhD from the San Raffaele Scientific Institute, Milan, Italy discusses minimal residual disease (MRD) negativity in chronic lymphocytic leukemia (CLL) at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark. Dr Ghia explains that MRD is a hot topic due to the multitude of new therapies that have become available. As it is still in early stages of development, it should only be used in the context of research according to Dr Ghia.

Share this video